Search research articles
Contact Us
Filters
Showing results (111-120 of 436) with videos related to
Page
of 44
Sort By:
American Journal of Clinical Pathology
|
June 15, 2016
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia
Juan Ouyang, Maitrayee Goswami, Jie Peng, et al.
American Journal of Hematology
|
March 29, 2021
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J Short, Marina Konopleva, Tapan Kadia, et al.
Leukemia Research
|
July 30, 2013
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
Naval Daver, Aditi Shastri, Tapan Kadia, et al.
American Journal of Hematology
|
January 28, 2025
Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia
Qing Wei, Shimin Hu, Sanam Loghavi, et al.
Blood Advances
|
September 30, 2021
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
David McCall, Michael Roth, Kris M Mahadeo, et al.
American Journal of Hematology
|
May 15, 2021
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Nitin Jain, Abhishek Maiti, Farhad Ravandi, et al.
Haematologica
|
August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
Gautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Leukemia & Lymphoma
|
April 30, 2025
A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm
Hannah Goulart, Guillermo Garcia-Manero, Tapan M Kadia, et al.
American Journal of Hematology
|
December 24, 2022
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens
Jayastu Senapati, Tareq Abuasab, Fadi G Haddad, et al.
American Journal of Hematology
|
November 2, 2012
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver, Paolo Strati, Elias Jabbour, et al.
Page
of 44
Search research articles
Search
Showing results (111-120 of 436) with videos related to
Sort By:
Page
of 44
American Journal of Clinical Pathology
|
June 15, 2016
Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia
Juan Ouyang, Maitrayee Goswami, Jie Peng, et al.
American Journal of Hematology
|
March 29, 2021
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J Short, Marina Konopleva, Tapan Kadia, et al.
Leukemia Research
|
July 30, 2013
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
Naval Daver, Aditi Shastri, Tapan Kadia, et al.
American Journal of Hematology
|
January 28, 2025
Chromoanagenesis Is Frequently Associated With Highly Complex Karyotypes, Extensive Clonal Heterogeneity, and Treatment Refractoriness in Acute Myeloid Leukemia
Qing Wei, Shimin Hu, Sanam Loghavi, et al.
Blood Advances
|
September 30, 2021
Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
David McCall, Michael Roth, Kris M Mahadeo, et al.
American Journal of Hematology
|
May 15, 2021
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Nitin Jain, Abhishek Maiti, Farhad Ravandi, et al.
Haematologica
|
August 10, 2012
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
Gautam Borthakur, Michael G Rosenblum, Moshe Talpaz, et al.
Leukemia & Lymphoma
|
April 30, 2025
A case series of oral decitabine-cedazuridine with venetoclax for blastic plasmacytoid dendritic cell neoplasm
Hannah Goulart, Guillermo Garcia-Manero, Tapan M Kadia, et al.
American Journal of Hematology
|
December 24, 2022
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens
Jayastu Senapati, Tareq Abuasab, Fadi G Haddad, et al.
American Journal of Hematology
|
November 2, 2012
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver, Paolo Strati, Elias Jabbour, et al.
Page
of 44